A Study of Personalized Neoantigen Cancer Vaccines
Completed
Conditions studied: Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma, Pancreatic Ductal Adenocarcinoma
In brief
The purpose of this study is 1) to evaluate the feasibility of manufacturing a patient-specific neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating a vaccine that encodes the predicted neoantigens; and, 2) to identify and select patients who may be eligible for a shared neoantigen cancer vaccine where their tumor contains a specific shared mutation and who have the correct HLA allele capable of presenting the neoantigen derived from the tumor-specific mutation.
Key facts
- Study ID
- NCT03794128
- Run by
- Gritstone bio, Inc.
- People needed
- 93
- Starts
- 2018-07-25
- Expected to finish
- 2020-05-26
- Last updated by the study team
- 2020-09-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois, United States
- Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center — New York, New York, United States
- The Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
- Tennessee Oncology — Nashville, Tennessee, United States
- Virginia Cancer Specialists — Fairfax, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.